Agios Pharmaceuticals Inc Stock Price, News & Analysis

Agios Pharmaceuticals (NASDAQ: AGIO) has announced its participation in major investor conferences scheduled for March 2022, specifically the Cowen 42nd Annual Virtual Healthcare Conference on March 7, 2022, and the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022. The live presentations will be accessible via the company’s website, and replays will be available for two weeks after each event. Agios specializes in therapies for genetically defined diseases, including a first-in-class treatment for PK deficiency.

Agios Pharmaceuticals has received FDA approval for PYRUKYND® (mitapivat) as the first treatment for hemolytic anemia in adults with PK deficiency. This marks a significant advancement in Agios' genetically defined disease portfolio. The company reported a net loss of $98.6 million for Q4 2021, increasing from $84.5 million in Q4 2020. As of Dec. 31, 2021, Agios holds $1.3 billion in cash and equivalents, ensuring strong financial stability to support ongoing clinical trials, including pivotal studies for thalassemia and sickle cell disease.

Agios Pharmaceuticals has received FDA approval for PYRUKYND® (mitapivat) to treat hemolytic anemia in adults with pyruvate kinase (PK) deficiency, marking it as the first disease-modifying therapy for this rare condition. The approval is based on the successful ACTIVATE and ACTIVATE-T Phase 3 studies. Agios plans to enhance patient access through programs offering $0 copays and free medications for eligible individuals. PYRUKYND® is expected to be available in the U.S. shortly. The European Medicines Agency is also reviewing the drug for potential approval by the end of 2022.

Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on February 24, 2022, at 8:00 a.m. ET to discuss its Q4 and year-end 2021 financial results. The event highlights Agios's commitment to transparency and communication with its investors. Interested parties can access the live webcast via the company’s website under the 'Events & Presentations' section. Agios is known for its innovative therapies targeting genetically defined diseases, especially in cellular metabolism and hemolytic anemias.

Agios Pharmaceuticals (AGIO) has outlined its key milestones for 2022, focusing on the anticipated FDA decision for mitapivat as a treatment for adults with PK deficiency due in February. The company plans five pivotal clinical trials across thalassemia, sickle cell disease, and pediatric PK deficiency. Agios aims to enhance its clinical portfolio, including the novel PK activator AG-946. With a strong cash position, Agios targets cash-flow positivity while expanding its research pipeline, expecting to achieve significant regulatory approvals by 2026.

Agios Pharmaceuticals (NASDAQ: AGIO) will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. Interested parties can access the live webcast under the "Events & Presentations" section of their website. A replay will be available for at least two weeks post-presentation. Agios focuses on developing novel medicines for genetically defined diseases, with a notable drug candidate, mitapivat, being evaluated for hemolytic anemias.

Agios Pharmaceuticals (NASDAQ: AGIO) presented new data on mitapivat at the ASH Annual Meeting, highlighting its long-term effectiveness in treating adults with pyruvate kinase (PK) deficiency. According to the findings, patients maintained significant hemoglobin responses for up to 21.9 months, with 35% of those switching to mitapivat achieving similar outcomes. The drug demonstrated improvements in ineffective erythropoiesis and iron overload, while bone mineral density remained stable in most patients over 5.5 years. Mitapivat is under regulatory review in the U.S. and EU as a potential treatment for PK deficiency.

Agios Pharmaceuticals initiated global Phase 3 studies, ENERGIZE and ENERGIZE-T, to evaluate mitapivat for treating α- and β-thalassemia. This follows promising long-term results from a Phase 2 trial, showing sustained hemoglobin improvements and a well-tolerated safety profile over 72 weeks. The study involved 20 patients, with a mean hemoglobin increase of 1.5 g/dL at Week 60 and 1.7 g/dL at Week 72. Mitapivat is not yet approved.

An investor webcast is scheduled for Dec. 14, 2021, to discuss findings presented at the ASH Annual Meeting.

Agios Pharmaceuticals announced promising data regarding mitapivat in treating sickle cell disease, presented at the ASH Annual Meeting. The investigational drug shows potential for clinically meaningful outcomes, including improved anemia and reduced hemolysis. Key findings from studies indicate that 83.3% of trial participants achieved a significant increase in hemoglobin levels, with no serious adverse events reported. The Phase 2/3 RISE UP study has been initiated to evaluate mitapivat's efficacy and safety, alongside a virtual investor event scheduled for December 14, 2021.